Search Results
Your search for ,Any matches 8112 pages
Showing 301 - 350WGS Liquid Biopsies for HPV-Associated Head and Neck Squamous Cell Carcinoma
Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) detection of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC), termed HPV-DeepSeek by the study investigators, showed greater sensitivity, specificity, and diagnostic accuracy than any current...
Chemotherapy-Free Neoadjuvant Therapy for HER2-Enriched Early Breast Cancer
In a German phase II trial (WSG-KEYRICHED-1) reported in The Lancet Oncology, Kuemmel et al evaluated whether chemotherapy-free neoadjuvant therapy with pembrolizumab plus trastuzumab/pertuzumab showed activity in patients with HER2-enriched early breast cancer. As stated by the investigators:...
Chemotherapy-Free Triplet in Previously Treated HR-Positive, HER2-Positive Advanced Breast Cancer
In a phase IIa study reported in The Lancet Oncology, Escrivá-de-Romani et al evaluated whether the chemotherapy-free triplet of the HER2-targeted bispecific antibody zanidatamab plus palbociclib and fulvestrant showed activity in heavily pretreated patients with hormone receptor (HR)-positive,...
Patient Advocacy Groups: Health-Care Programs Are Lifelines—Not Line Items
Forty nonprofit, nonpartisan organizations issued a statement this week to the House Energy & Commerce and Ways & Means Committees in regard to budget cuts and policy changes affecting Medicaid and health-care marketplaces. “As organizations representing millions of patients with serious...
First-Line TFOX vs FOLFOX in Advanced HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma
In a French phase III trial (PRODIGE 51-FFCD-GASTFOX) reported in The Lancet Oncology, Zaanan et al found that a modified FLOT (fluorouracil, oxaliplatin, and docetaxel) regimen known as TFOX (docetaxel, folinic acid, oxaliplatin, and fluorouracil) improved outcomes vs FOLFOX (folinic acid,...
NCCN Clinical Practice Guidelines in Oncology: 2025 Updates
The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are available for more than 60 tumor types, subtypes, and related topics. During the NCCN’s 30th Annual...
In Case You Missed It: Additional Abstracts of Interest From AACR
Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers...
Effects of Tumor-Infiltrating Clonal Hematopoiesis
In a study reported in The New England Journal of Medicine, Pich et al found that tumor-infiltrating clonal hematopoiesis (TI-CH) was associated with an increased risk of death or recurrence among patients with early-stage non–small cell lung cancer (NSCLC) and poorer overall survival among...
Early-Onset Breast, Colorectal, Endometrial, Pancreatic, and Kidney Cancers on the Rise
Recent studies have shown increasing rates of early-onset cancers, often defined as cancers occurring in people younger than age 50, especially colorectal, pancreatic, female breast, and uterine cancers, and younger birth cohorts seem to have a higher risk of some cancer types compared with older...
Patterns in Oncology Drug Use After Accelerated Approval Is Withdrawn
The accelerated approval program of the U.S. Food and Drug Administration (FDA) allows certain medications to be marketed if they are indicated for serious disease and there has been preliminary evidence of the drug’s efficacy. Pharmaceutical companies must then conduct postapproval trials to...
How Could So Many Physicians Have Failed Me?
The first sign that something was terribly wrong was in 2015, when I began to feel so fatigued that it was difficult to get out of bed even after 8 to 10 hours of sleep. I’ve been full of energy my whole life and couldn’t understand why I was so tired all the time. Then I began to experience...
Joint Clinical Practice Guideline Addresses Opioid Conversion for Patients With Cancer
Several medical organizations recently released a joint Clinical Practice Guideline to provide recommendations on opioid conversion in adults with cancer.1 ASCO, together with the Multinational Association of Supportive Care in Cancer (MASCC), American Academy of Hospice and Palliative Medicine,...
Final Overall Survival Data: Amivantamab-vmjw Plus Lazertinib vs Osimertinib in EGFR-Mutated Non–Small Cell Lung Cancer
The phase III MARIPOSA trial was a head-to-head comparison of the EGFR tyrosine kinase inhibitor osimertinib and the combination of the bispecific EGF receptor–directed and MET receptor–directed monoclonal antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib in the first-line ...
Quick Takes on Research Findings on Novel Therapies for Gynecologic Cancers
The 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer advanced the field with updates of practice-changing trials and other research that challenges the conventional approaches to treating gynecologic cancers. We have briefly captured some of that research here for readers ...
Everolimus Plus Lanreotide vs Everolimus Alone in Aggressive Gastroenteropancreatic Neuroendocrine Tumors
In patients with aggressive gastroenteropancreatic neuroendocrine tumors, first-line treatment with the mTOR inhibitor everolimus and the somatostatin analog lanreotide more than doubled the median progression-free survival for patients vs everolimus alone, in the phase III JCOG1901 (STARTER-NET)...
Addition of Perioperative Pembrolizumab to Standard of Care in Newly Diagnosed Locally Advanced Head and Neck Cancer
In the phase III KEYNOTE-689 trial, perioperative use of the PD-1 inhibitor pembrolizumab given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated patients with locally advanced head and neck squamous cell carcinoma, researchers reported at the ...
Adavosertib in Recurrent or Persistent Uterine Serous Carcinoma
In the phase IIb ADAGIO trial, reported in the Journal of Clinical Oncology, Liu et al found that the Wee1 inhibitor adavosertib showed some activity in patients with recurrent or persistent uterine serous carcinoma. However, its use was associated with high toxicity rates. Study Details In the...
Use of Ruxolitinib to Resolve Ciltacabtagene Autoleucel–Induced Parkinsonism in Patients With Multiple Myeloma
Ruxolitinib may prove to be an effective treatment of parkinsonism arising from ciltacabtagene autoleucel treatment for patients with multiple myeloma, according to the results of a case report published in the Journal of Hematology. The report featured two cases of patients with multiple myeloma...
Venetoclax-Based Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia
“Knowledge is like a lion; it cannot be gently embraced.” –South African Proverb Long-term efficacy and safety confirm that a hypomethylating agent and venetoclax is an improvement in the standard of care for patients with AML who are not eligible for intensive chemotherapy because of advanced age...
AACR 2025: Nonoperative Management of Mismatch Repair–Deficient Tumors
PD-1 blockade with the PD-1 inhibitor dostarlimab-gxly induced complete tumor clearance and resolved the need for surgery in patients with locally advanced, mismatch repair–deficient (dMMR) cancers, according to preliminary results from a phase II trial presented at the 2025 American Association...
Childhood Exposure to Bacterial Toxin May Trigger Early-Onset Colorectal Cancer
Researchers may have identified the bacterial toxin colibactin as a potential factor contributing to the concerning rise in early-onset colorectal cancer, according to a novel study published by Díaz-Gay et al in Nature. The findings demonstrated a substantial enrichment of colibactin-related...
Raising Awareness of Inflammatory Breast Cancer
In late January 2013, while playing with my young son, I noticed my left breast seemed slightly larger than my right breast. Although, at the time, I had no idea this type of swelling is a hallmark of inflammatory breast cancer, a rare and aggressive disease, I immediately made an appointment with...
Managing Dermatologic Reactions to Combination Therapy for Patients With EGFR-Mutated NSCLC
Nicolas Girard, MD, a thoracic oncologist at the Institut Curie, Paris, presented the results of an interim analysis of the open-label phase II COCOON study, at the European Lung Cancer Congress (ELCC) 2025.1 A readily available preventive regimen (the COCOON regimen) reduced moderate-to-severe...
Hyperefficient and Super-Digitized Health Care: Where Is the Smile?
A few weeks ago, a family member underwent a minor outpatient operative procedure. From a few weeks before the scheduled date of the procedure, multiple text messages and e-mails were forwarded to provide preparatory instructions for the procedure. The day before the procedure, another...
Some Patients With Advanced NSCLC Experience Durable Disease Control After Immunotherapy Discontinuation
Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape over the last decade for patients with non–small cell lung cancer (NSCLC), the agents can also stimulate uncontrolled immunity against normal tissues and organs, leading to a cascade of immune-related adverse...
Activity of ROS1 TKI in NSCLC
In a pooled analysis of the phase II TRUST-I and TRUST-II trials reported in the Journal of Clinical Oncology, Pérol et al found that the oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI) taletrectinib was highly active in ROS1-positive advanced or metastatic ...
Low-Dose vs Regular-Dose Apixaban for Prevention of VTE Recurrence in Patients With Cancer
Patients with active cancer who developed venous thromboembolism (VTE) and were treated with anticoagulants for at least 6 months, followed by an additional 12 months of low-dose apixaban, experienced similar VTE recurrences and less bleeding as similar patients who received a full dose of the oral ...
Invitation to Colonoscopy vs Fecal Immunochemical Test Screening for Colorectal Cancer
In a Spanish study (COLONPREV) reported in The Lancet, Castells et al found that invitation to fecal immunochemical test (FIT) vs colonoscopy screening for colorectal cancer was associated with noninferiority in colorectal cancer mortality. Study Details In the multicenter study, eligible...
Talazoparib Plus Enzalutamide in Advanced Prostate Cancer: Patient-Reported Outcomes
In an analysis from the phase III TALAPRO-2 trial reported in The Lancet Oncology, Matsubara et al found that first-line talazoparib plus enzalutamide was associated with prolonged time to definitive deterioration in global health status/quality of life (GHS/QOL) vs placebo plus enzalutamide in...
NK Cells Complexed With Bispecific Antibody May Be of Benefit to Patients With Lymphoma
A novel cell therapy approach using cord blood–derived natural killer (NK) cells precomplexed with the CD30/CD16A bispecific antibody AFM13 may be safe and generate responses in patients with refractory CD30-positive lymphomas, according to a recent study published by Nieto et al in Nature...
Rates of Breast, CRC Screenings Almost Four Times Higher Than Lung Cancer Screenings
Many patients who are eligible for lung cancer screening do not receive it, but do receive preventative screenings for other cancer types, according to the results of a new study published by Potter et al in JAMA. Background Although lung cancer screening is recommended for certain individuals...
Radiation Therapy: Hypofractionation vs Conventional Fractionation in Patients With Breast Cancer Planning Breast Reconstruction
Postmastectomy radiation therapy may be significantly shortened for many patients planning breast reconstruction, according to data from a large phase III trial (RT CHARM, Alliance A221505).1 Investigators reported that hypofractionated (short-course) radiation therapy was found to be noninferior...
Proton Therapy and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer
Proton beam therapy and intensity-modulated radiation therapy (IMRT) were found to offer equivalent quality-of-life outcomes for patients with localized prostate cancer, according to data from the PARTIQoL trial. This phase III trial showed no measurable differences between the two approaches in...
Machine Learning Program May Enhance Transplantation Risk Assessment in Patients With Myelofibrosis
A novel machine learning model may outperform standard statistical models in identifying and stratifying transplantation risk among patients with myelofibrosis, according to a recent study published by Hernández-Boluda et al in Blood. Background Although there are several therapies available to...
Low-Dose CT Screening for Lung Cancer in a High-Risk Population
In a UK prospective longitudinal cohort study (SUMMIT) reported in The Lancet Oncology, Bhamani et al found that large-scale, low-dose computed tomography (CT) screening for lung cancer is effective and “can be delivered efficiently” in a diverse high-risk population. As stated by the...
Daily Physical Activity—Even at Light Intensities—May Reduce Cancer Risk
Investigators found that individuals who engaged in light- and moderate-to-vigorous–intensity physical activity daily had a lower risk of developing cancer compared with those who were more sedentary, according to a recent study published by Shreves et al in the British Journal of Sports Medicine....
Active Surveillance vs Standard Surgery After Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer
In a Dutch noninferiority phase III trial (SANO) reported in The Lancet Oncology, van der Wilk et al found that active surveillance was noninferior to standard surgery in terms of 2-year overall survival among patients with esophageal cancer who had a clinical complete response after neoadjuvant...
Neoadjuvant Nivolumab Plus Chemotherapy and Response-Stratified CRT in HPV-Negative Head and Neck Cancer
In a single-center phase II trial (DEPEND) reported in JAMA Oncology, Rosenberg et al found that the combination of neoadjuvant nivolumab and chemotherapy followed by response-stratified chemoradiation (CRT) was active in human papillomavirus (HPV)-negative stage IVa/b head and neck squamous cell...
Interventions to Improve Uptake of FIT Colorectal Cancer Screening in Scotland
In a Scottish study (TEMPO) reported in The Lancet, Robb et al found that a behavioral intervention adding a deadline for fecal immunochemical testing (FIT) return in the invitation letter to FIT colorectal cancer screening resulted in superior uptake of testing. Study Details In the trial, 40,000...
Building and Sharing Dietary Evidence in Cancer Care
Guest Editor’s Note: Several epidemiologic studies have shown an inverse association between healthy dietary patterns and the risk of chronic diseases including cancer. Patients are often interested in exploring different dietary interventions throughout the cancer continuum. However, concrete...
Lifetime Body Weight Patterns Could Affect Risk of Developing Renal Cell Carcinoma
Weight patterns throughout life may affect an individual’s likelihood of developing renal cell carcinoma, according to a recent study published by Deng et al in Cancer. Study Methods and Results In the study, investigators used data from the NIH-AARP Diet and Health Study to assess weight patterns...
Pembrolizumab Plus Chemotherapy: New Standard of Care in Locally Advanced Cervical Cancer?
Updated findings from the second planned interim analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study solidify the PD-1 inhibitor pembrolizumab plus concurrent chemoradiotherapy, followed by pembrolizumab maintenance, as the upfront standard of care for high-risk, locally advanced...
HER2-Selective TKI in Advanced Solid Tumors with HER2 Alterations
In a phase Ia/Ib study (Beamion LUNG-1) reported in the Journal of Clinical Oncology, Heymach et al evaluated the safety profile and activity of zongertinib in patients with HER2-altered solid tumors. Zongertinib is a novel HER2-selective tyrosine kinase inhibitor (TKI) that spares EGFR, thereby...
TB Vaccination Could Enhance BCG Response in Patients With Non–Muscle-Invasive Bladder Cancer, Study Finds
Two doses of a simple tuberculosis (TB) vaccination after surgery helps the immune system fight cancer cells and may improve patient outcomes among those with non–muscle-invasive bladder cancer, according to a pilot study of 40 patients. Initial results from the RUTIVAC-1 Trial were presented by...
Screening Was Key to the Early Detection of My Prostate Cancer
As a Native American and former president of the Seneca Nation of Indians, I am keenly aware of the disparities in cancer care we face in accessing screening and treatment, which results in worse survival rates compared with those of racial and ethnic populations.1 Native American and Alaska Native ...
Bringing Palliative Care to Every Patient With Cancer
Janet L. Abrahm, MD, FACP, FAAHPM, FASCO, has spent more than half of her oncology career as a palliative care physician. After receiving her medical degree from the University of California, San Francisco (UCSF), in 1973, Dr. Abrahm completed her internship and residency at Massachusetts General...
Colorectal Cancer May Be Linked to Heightened Risk of Cardiovascular Mortality
The risk of death from cardiovascular causes may be higher among patients diagnosed with colorectal cancer compared with the general population, according to new findings presented by Ayaz et al at the American College of Cardiology (ACC) Annual Scientific Session 2025. Background Cardiovascular...
Neoadjuvant Chemoradiotherapy Plus Immunotherapy in Esophageal Squamous Cell Carcinoma
Neoadjuvant therapy that combines chemotherapy, radiotherapy, and the investigational PD-1 inhibitor sintilimab led to a significantly higher pathologic complete response rate in patients with locally advanced esophageal squamous cell carcinoma, according to data presented at the 2025 ASCO...
Advancing Clinical Decisions With Circulting Tumor DNA: Insights From Recent Clinical Trials
Circulating tumor DNA (ctDNA) has evolved from an experimental biomarker to an increasingly actionable tool, informing treatment decisions throughout colorectal cancer care. Whether guiding adjuvant therapy intensification or de-escalation, refining organ-preservation strategies in rectal cancer,...
Exploratory Post Hoc Analysis of DUO-E Reveals Olaparib’s Benefit in Endometrial Cancer Subsets
The phase III DUO-E study evaluated the addition of the monoclonal antibody durvalumab to chemotherapy, and the benefit of maintenance durvalumab, with and without the PARP inhibitor olaparib, in advanced endometrial cancer. As reported this past year,1 the inclusion of durvalumab reduced the risk...
